- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00768755
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
October 6, 2015 updated by: Pfizer
Randomized Phase 2 Study Of Cisplatin/Pemetrexed With Or Without Axitinib (AG-013736) As First-Line Treatment For Patients With Non-Squamous Non-Small Cell Lung Cancer
AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
180
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Genova, Italy, 16132
- Pfizer Investigational Site
-
Lido di Camaiore (LU), Italy, 55043
- Pfizer Investigational Site
-
Orbassano (TO), Italy, 10043
- Pfizer Investigational Site
-
-
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan
- Pfizer Investigational Site
-
-
-
-
-
Lubin, Poland, 59-300
- Pfizer Investigational Site
-
Otwock, Poland, 05-400
- Pfizer Investigational Site
-
Pila, Poland, 64-920
- Pfizer Investigational Site
-
Poznan, Poland, 61-485
- Pfizer Investigational Site
-
Poznan, Poland, 60-569
- Pfizer Investigational Site
-
Prabuty, Poland, 82-550
- Pfizer Investigational Site
-
Warszawa, Poland, 00-909
- Pfizer Investigational Site
-
-
-
-
-
Bacau, Romania, 600114
- Pfizer Investigational Site
-
Iasi, Romania, 700106
- Pfizer Investigational Site
-
-
-
-
-
Moscow, Russian Federation, 115478
- Pfizer Investigational Site
-
Pyatigorsk, Russian Federation, 357502
- Pfizer Investigational Site
-
Saint-Petersburg, Russian Federation, 197089
- Pfizer Investigational Site
-
St.Petersburg, Russian Federation, 194044
- Pfizer Investigational Site
-
-
-
-
-
Castellon, Spain, 12002
- Pfizer Investigational Site
-
Madrid, Spain, 28007
- Pfizer Investigational Site
-
Madrid, Spain, 28041
- Pfizer Investigational Site
-
Palma de Mallorca, Spain, 07010
- Pfizer Investigational Site
-
Sevilla, Spain, 41009
- Pfizer Investigational Site
-
-
Barcelona
-
Terrassa, Barcelona, Spain, 08221
- Pfizer Investigational Site
-
-
-
-
-
Basel, Switzerland, CH-4031
- Pfizer Investigational Site
-
Basel, Switzerland, CH-4016
- Pfizer Investigational Site
-
Bruderholz, Switzerland, CH-4101
- Pfizer Investigational Site
-
Liestal, Switzerland, CH-4410
- Pfizer Investigational Site
-
-
-
-
-
Taichung, Taiwan, 40705
- Pfizer Investigational Site
-
Taichung, Taiwan, 402
- Pfizer Investigational Site
-
Taipei, Taiwan, 100
- Pfizer Investigational Site
-
Taipei, Taiwan, 112
- Pfizer Investigational Site
-
-
-
-
-
Dnipropetrovsk, Ukraine, 49102
- Pfizer Investigational Site
-
Kyiv, Ukraine, 03115
- Pfizer Investigational Site
-
-
-
-
-
Bournemouth, United Kingdom, BH7 7DW
- Pfizer Investigational Site
-
Brighton, United Kingdom, BN2 5BE
- Pfizer Investigational Site
-
Dundee, United Kingdom, DD1 9SY
- Pfizer Investigational Site
-
Middlesex, United Kingdom, HA6 2RN
- Pfizer Investigational Site
-
Poole, United Kingdom, BH15 2JB
- Pfizer Investigational Site
-
-
Essex
-
Romford, Essex, United Kingdom, RM7 0AG
- Pfizer Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, United Kingdom, HA6 2RN
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35805
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30341
- Pfizer Investigational Site
-
Decatur, Georgia, United States, 30033
- Pfizer Investigational Site
-
Macon, Georgia, United States, 31217
- Pfizer Investigational Site
-
Marietta, Georgia, United States, 30060
- Pfizer Investigational Site
-
Sandy Springs, Georgia, United States, 30342
- Pfizer Investigational Site
-
-
Illinois
-
Bloomington, Illinois, United States, 61701
- Pfizer Investigational Site
-
Peoria, Illinois, United States, 61615
- Pfizer Investigational Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033-0850
- Pfizer Investigational Site
-
West Reading, Pennsylvania, United States, 19611
- Pfizer Investigational Site
-
-
Rhode Island
-
East Providence, Rhode Island, United States, 02914
- Pfizer Investigational Site
-
East Providence, Rhode Island, United States, 02915
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of adeno-, large cell or bronchioalveolar non-small cell lung cancer
- Cytologic specimens for diagnosis or for cell type classification must have been obtained from bronchial brushings or washings or from needle aspiration of a defined lesion. Sputum cytology alone will not be acceptable for diagnosis or for cell type classification.
- Patients with mixed NSCLC with predominantly squamous cell carcinoma should be classified as squamous and thus do not qualify for this study.
- Stage IIIB with malignant effusion (with cytologic confirmation of malignant pleural or pericardial effusion), Stage IV, or recurrent disease after definitive loco-regional therapy.
- Candidate for primary treatment with cisplatin and pemetrexed
Exclusion Criteria:
- Any histological/cytological evidence of predominantly squamous NSCLC.
- Small cell or carcinoid lung cancer patients are also ineligible.
- NSCLC that cannot be classified as one of the eligible histologies (adenocarcinoma, large cell or bronchioalveolar).
- Prior systemic therapy for Stage IIIB (with malignant effusion), Stage IV, or recurrent NSCLC. (Prior treatment with systemic therapy as adjuvant chemotherapy or in conjunction with radiotherapy for Stage II or III NSCLC is permitted if the last dose of chemotherapy was completed 12 months or more prior to randomization).
- Prior treatment with a VEGF or VEGFR inhibitor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: I
Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
|
5mg BID po up to max 10mg BID po
Other Names:
5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
Other Names:
5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
|
Experimental: II
Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
|
5mg BID po up to max 10mg BID po
Other Names:
5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
Other Names:
5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
|
Active Comparator: III
pemetrexed and cisplatin
|
Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
Other Names:
|
Experimental: IV
Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
|
5mg BID po up to max 10mg BID po
Other Names:
5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
Other Names:
5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
|
Active Comparator: V
pemetrexed and cisplatin
|
Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Phase 2 baseline until the date of first documented progression or death due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
|
Time in months from the date of randomization to first documentation of objective tumor progression or death due to any cause.
PFS was calculated as (first event date minus minus the date of randomization plus 1) divided by 30.4.
Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]); death was determined from AE data (where the outcome was "Death") or from the end of study data.
|
Phase 2 baseline until the date of first documented progression or death due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Baseline until death or collected bimonthly following discontinuation of study treatment until at least 1 year after randomization of the last participant
|
Time in months from the date of randomization to date of death due to any cause.
OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.
Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death).
|
Baseline until death or collected bimonthly following discontinuation of study treatment until at least 1 year after randomization of the last participant
|
Percentage of Participants With Objective Response (OR)
Time Frame: Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
|
Percentage of participants with OR based assessment of confirmed complete response (CR)/confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors(RECIST).Confirmed responses: those persist on repeat imaging study at least 4 weeks after initial documentation of response.CR: disappearance of all lesions (target/non target) and no appearance of new lesions.PR: those with at least 30 % decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions,without progression of non target lesions and no appearance of new lesions.
|
Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
|
Duration of Response (DR)
Time Frame: Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
|
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause, whichever occurs first.
Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4.
DR was calculated for the subgroup of participants with a confirmed objective tumor response.
|
Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
|
Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Severity Score
Time Frame: Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and end of treatment (EOT)
|
Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine.
Lower scores indicated better outcome.
|
Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and end of treatment (EOT)
|
Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Interference Score
Time Frame: Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and EOT
|
Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely.
Lower scores indicated better outcome.
|
Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and EOT
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
October 7, 2008
First Submitted That Met QC Criteria
October 7, 2008
First Posted (Estimate)
October 8, 2008
Study Record Updates
Last Update Posted (Estimate)
October 28, 2015
Last Update Submitted That Met QC Criteria
October 6, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Folic Acid Antagonists
- Axitinib
- Pemetrexed
Other Study ID Numbers
- A4061039
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on axitinib
-
PfizerCompletedNeoplasmsPoland, United States, Spain
-
Peking University Cancer Hospital & InstituteUnknownAdvanced Mucosal MelanomaChina
-
Acceleron Pharma Inc. (a wholly owned subsidiary...TerminatedAdvanced Renal Cell CarcinomaUnited States
-
PfizerCompletedLung Neoplasms | Carcinoma, Non-small Cell LungUnited States, Germany
-
PfizerCompletedCarcinoma, Renal CellUnited States, Spain, Japan, Germany, Czechia, Russian Federation
-
Chinese University of Hong KongCompleted
-
University of Wisconsin, MadisonPfizerCompletedSolid Malignancies | Metastatic Castrate-resistant Prostate CancerUnited States
-
Spanish Cooperative Group for the Treatment of...TerminatedColorectal CarcinomaSpain
-
AkesoRecruitingRenal Cell Carcinoma | First-line TreatmentChina
-
Assistance Publique - Hôpitaux de ParisPfizerCompletedcT2a N0NxM0 Renal TumorFrance